deltatrials
Recruiting PHASE1 INTERVENTIONAL 1-arm NCT04991948

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

An Open-label, Phase Ib Study to Assess the Safety and Clinical Activity of CYAD-101 Administered Concurrently With FOLFOX Chemotherapy, Followed by Pembrolizumab Treatment, in Patients With Metastatic Colorectal Cancer

Sponsor: Celyad Oncology SA

Conditions Unresectable Metastatic Colorectal Cancer
Interventions CYAD-101 FOLFOX Pembrolizumab
Updated 5 times since 2021 Last updated: Feb 22, 2022 Started: Nov 22, 2021 Primary completion: Aug 21, 2023 Completion: May 25, 2038
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04991948, this PHASE1 trial focuses on Unresectable Metastatic Colorectal Cancer and remains actively recruiting participants. Sponsored by Celyad Oncology SA, it has been updated 5 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshotNot Yet Recruiting~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotRecruiting

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Recruiting PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  3. Jun 2022 — Jul 2024 [monthly]

    Recruiting PHASE1

  4. Apr 2022 — Jun 2022 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  5. Sep 2021 — Apr 2022 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celyad Oncology SA
  • Merck Sharp & Dohme LLC
Data source: Celyad Oncology SA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations